Pirfenidone for the lungs: Extent of added benefit assessed

Pirfenidone inhibits the development of inflammation and scarring in lung tissue and has been approved for the treatment of idiopathic pulmonary fibrosis since the beginning of 2011. The added benefit from pirfenidone is accompanied by greater harm in the form of adverse events, according to researchers. The overall conclusion of a recent evaluation is that the extent of added benefit from pirfenidone should be classified as "no proven added benefit."

Read the whole article on Science Daily

More from Science Daily